Sfen - in English’s Post

☢️🚀 !Exciting News from Curium Pharma! 🚀☢️ Curium Pharma has submitted its 505(b)(2) New Drug Application for Lu-177 Dotatate Injection to the FDA! This groundbreaking therapy targets somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). 🎯 This submission is a major milestone in Curium's journey to revolutionize cancer treatment through advanced nuclear medicine. 💬 Michael Patterson, Curium North America's CEO, stated: "Our application for Lutetium Lu 177 Dotatate Injection marks an important step towards making nuclear medicine-based cancer therapies more accessible and reliable for patients and caregivers." #CuriumPharma #NuclearMedicine #CancerTreatment #FDA #Innovation #Healthcare #PharmaNews #MedicalAdvancement #CancerResearch #PatientCare #RadioligandTherapy #Biotech

Nucleus RadioPharma 𝗵𝗮𝘀 𝗳𝗼𝗿𝗴𝗲𝗱 𝗶𝘁𝘀 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝗔𝗥𝗧𝗕𝗜𝗢, 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, 𝘁𝗼 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲 𝗣𝗯𝟮𝟭𝟮-𝗿𝗮𝗱𝗶𝗼𝗹𝗮𝗯𝗲𝗹𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗼𝗿 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. This collaboration underscores Nucleus' mission as the world's first integrated development, manufacturing, and supply chain organization for radiopharmaceuticals. Focusing on addressing manufacturing and supply chain challenges, Nucleus aims to streamline production timelines and alleviate constraints in the delivery of nuclear medicines. This partnership highlights the growing interest in radiopharmaceuticals and the efforts to overcome manufacturing and logistical hurdles in the field. https://lnkd.in/ekWKq66C #Radiopharmaceuticals #SupplyChain #NuclearMedicine #HealthcareInnovation #PharmaceuticalIndustry

PanMediso Spotlight｜Another MNC Joins the Radiopharmaceutical Race with a €320 Million Deal On September 12, 2024, Sanofi reached an exclusive licensing agreement valued at approximately €320 million with RadioMedix and Orano Med to co-develop radioligand therapy (RLT) based on the radioactive isotope 212Pb for cancer treatment. The core of the collaboration is the AlphaMedix project, an alpha particle-targeted therapy (TAT) designed to treat patients with neuroendocrine tumors (NET) expressing somatostatin receptors. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Radiopharmaceutical #Cancer #Sanofi #RadioMedix #OranoMed #212Pb #RLT #AlphaMedix

This $825M upfront payment deal between Arrowhead (siRNA company) and Sarepta (Biopharma) further validates the value of RNA-targeting technology. Despite siRNA has been successful in targeting Cytoplasmic RNAs, it's not potent in targeting Nuclear RNAs, which are key disease drivers in many neurodegenerative diseases. NuCyRNA Therapeutics has demonstrated robust co-targeting of both Nuclear & Cytoplasmic RNAs based on our next-gen oligo technology. We are developing 2 innovative programs in neurodegenerative diseases. DM me or email info@nucyrnatx.com to learn more! #RNA, #neurodegeneration, #ALS, #Aging

The European Medicines Agency (EMA) has published a concept paper on the Clinical Evaluation of Therapeutic Radiopharmaceuticals in Oncology, paving the way for a full guideline in 2025. This document highlights unique regulatory considerations and aims to provide targeted guidance for applying EU legislation to the clinical development of therapeutic radiopharmaceuticals. 🗓 A public consultation is open until January 31, 2025! Stakeholders are invited to review the draft and submit feedback. The EANM is preparing a unified response and welcomes collaboration with organisations and societies to ensure aligned feedback on behalf of the European nuclear medicine community. 📩 Contact us at euaffairs@eanm.org to align responses or learn more about the EANM’s position! 🔗 Read the concept paper here: https://lnkd.in/dK7E67gw

📣 Actinium-225 License Agreement with our Chinese Joint Venture ✨ Today, Eckert & Ziegler has signed a 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗤𝗶 𝗞𝗮𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹, Ltd (QKM), our 𝗷𝗼𝗶𝗻𝘁 𝘃𝗲𝗻𝘁𝘂𝗿𝗲 𝘄𝗶𝘁𝗵 𝗗𝗖 𝗣𝗵𝗮𝗿𝗺𝗮, for our 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗽𝗿𝗼𝗱𝘂𝗰𝗲 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (Ac-225). ⚛️ 💡 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻? 💰 A one-time 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝗼𝗳 𝗘𝗨𝗥 𝟭𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗿𝗼𝘆𝗮𝗹𝘁𝗶𝗲𝘀 for Eckert & Ziegler. 🌐 Strengthening our position as a 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘀𝘂𝗽𝗽𝗹𝗶𝗲𝗿 𝗼𝗳 𝗔𝗰-𝟮𝟮𝟱 for the global radiopharmaceutical industry. 📈 Substantial 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝗚𝗠𝗣-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝗰-𝟮𝟮𝟱 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝟮𝟬𝟮𝟱 onward. 𝗪𝗵𝘆 𝗔𝗰-𝟮𝟮𝟱 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Ac-225 is showing 𝗶𝗺𝗺𝗲𝗻𝘀𝗲 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 like prostate tumors, colorectal cancer, and leukemia. As 𝗱𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗔𝗰-𝟮𝟮𝟱 𝘀𝘂𝗿𝗴𝗲𝘀, this collaboration helps address the scarcity of this critical therapeutic isotope, ensuring patients benefit from its potential. 🙌 This agreement is a testament to our commitment to 𝗽𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 for a healthier tomorrow.💙 #Actinium225 #Radiopharmaceuticals #NuclearMedicine #RadioligandTherapy #ContributingToSavingLives  

More radiopharmaceutical action as AstraZeneca snaps up its partner Fusion Pharmaceuticals for a cool $2 billion up-front. These targeted, radiation-carrying warheads are, we hear, the new frontier in cancer care: they do for external beam radiation therapy what precision medicine has done for chemotherapy, that other treatment mainstay. As with antibody-drug-conjugates, there's lots to play with: isotopes, ligand type, target, chelator chemistry...and the "art" of bringing all these together to form something stable that won't degenerate before it reaches its target (experts tell me this part is, for now, 'more art than science'). Alpha-emitting actinium-225 looks the coolest isotope right now, but shorter-lived lead-212 is among those snapping at its heels.... More from me soon on this topic, which of course faces challenges: how do you get enough isotope? How do you get the stuff to patients before it decays? What about 'radio-phobia'? Where are all the nuclear medicine physicians? Shout if you know someone chasing an unusual target, or using an unusual isotope. https://lnkd.in/enRVq4Yy https://lnkd.in/ep9J2VkA

PanMediso Spotlight｜Big Moves for Nuclear Drug——Novartis April 30, 2024 - Novartis expanded its cooperation with PeptiDream on peptide discovery. PeptiDream's innovative Peptide Discovery Platform System (PDPS®) can identify and optimise novel macrocyclic peptides for potential radionuclide binding and therapeutic diagnostics. PeptiDream will receive the downpayment of $180 million and is likely to receive up to $2.71 billion in in milestone payments and sales splits! May 2 2024 - Novartis announced the acquisition of Mariana Oncology, gaining access to its pipeline of nuclear medicines, including breast, prostate and lung cancers, including the investigational small-cell lung cancer candidate MC-339. Novartis will make an upfront payment of USD 1 billion and an additional payment of USD 750 million upon achievement of predetermined milestones. As a radioligand therapy (RLT) R&D company, PanMediso Holdings will continue to concentrate on the latest industry trends, strengthen the international cooperation, and establish a close global partnership to make more innovative breakthroughs in personalized treatment and targeted therapy with aim of improving the treatment effect for patients. #Novartis #PeptiDream #MarianaOncology #nuclearmedicine #macrocyclicpeptide #pharmaceuticalcooperation 

𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗕𝗲𝗴𝗶𝗻𝘀 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 🚀 Today, we celebrate the successful c𝗼𝗺𝗺𝗲𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (𝗔𝗰-𝟮𝟮𝟱) 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 together with our partners at the Nuclear Physics Institute CAS. 🎉 🔬 𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 This milestone of our 𝗰𝗼𝗺𝗺𝗼𝗻 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 addresses a 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲 of this critical radionuclide. Ac-225 is vital for developing 𝗮𝗹𝗽𝗵𝗮-𝗲𝗺𝗶𝘁𝘁𝗶𝗻𝗴 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, a promising approach in targeted cancer therapies. Our 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻-𝗯𝗮𝘀𝗲𝗱 production of 𝗔𝗰-𝟮𝟮𝟱 𝗳𝗿𝗼𝗺 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟲 is a pivotal advancement, ensuring reliability and scalability for 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. 💡 𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘅𝘁? We’ve initiated validation processes for 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗔𝗰-𝟮𝟮𝟱, expected to be available in the 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟱. This breakthrough will unlock 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 and support the development of potentially 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀. 🤝 𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝘆 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 This achievement was made possible through our 𝘀𝘁𝗿𝗼𝗻𝗴 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗣𝗵𝘆𝘀𝗶𝗰𝘀 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗖𝘇𝗲𝗰𝗵 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 (ÚJF) and the 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 of the team at Eckert & Ziegler Hot Cells. With this success, Eckert & Ziegler continues to 𝗹𝗲𝗮𝗱 𝘁𝗵𝗲 𝘄𝗮𝘆 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, ensuring a 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀 for a brighter future in nuclear medicine 🔗 Read the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 for more details — 𝗟𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 ⬇️ #Actinium225 #NuclearMedicine #Radiopharmaceuticals #AlphaTherapy #ContributingToSavingLives  

Thanks for sharing Jeevan! This is a great article covering the history and future directions for radiopharmaceuticals. While there are many aways to describe this treatment my favorite has always been "phenotypic precision medicine" however "molecular missiles" now is a close second. #RLT #PSMA